Meningitis Research Today is a free monthly online journal that collates and summarizes the latest research about Meningitis, including details on viral, bacterial, spinal, symptoms, treatment.

Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7.

Norheim G, Aseffa A, Yassin MA, Mengistu G, Kassu A, Fikremariam D, Tamire W, Merid Y, Høiby EA, Caugant DA, Fritzsønn E, Tangen T, Alebel T, Berhanu D, Harboe M, Rosenqvist E

Division of Infectious Disease Control, Norwegian Institute of Public Health (NIPH), Oslo, Norway.

To elucidate critical components of protective immune responses induced during the natural course of serogroup A meningococcal disease, we studied acute-, early-convalescent-, and late-convalescent-phase sera from Ethiopian patients during outbreaks in 2002 to 2003. Sera were obtained from laboratory-confirmed patients positive for serogroup A sequence type 7 (ST-7) meningococci (A:4/21:P1.20,9) (n = 71) and from Ethiopian controls (n = 113). The sera were analyzed using an enzyme-linked immunosorbent assay to measure levels of immunoglobulin G (IgG) against serogroup A polysaccharide (APS) and outer membrane vesicles (OMVs) and for serum bactericidal activity (SBA) using both rabbit and human complement sources. Despite relatively high SBA titers and high levels of IgG against APS and OMVs in acute-phase patient sera, significant increases were seen in the early convalescent phase. Antibody concentrations returned to acute-phase levels in the late convalescent phase. Considering all patients' sera, a significant but low correlation (r = 0.46) was observed between SBA with rabbit complement (rSBA) using an ST-5 reference strain and SBA with human complement (hSBA) using an ST-7 strain from Ethiopia. While rSBA demonstrated a significant linear relation with IgG against APS, hSBA demonstrated significant linear relationships with IgG against both APS and OMV. This study indicates that antibodies against both outer membrane proteins and APS may be important in providing the protection induced during disease, as measured by hSBA. Therefore, outer membrane proteins could also have a role as components of future meningococcal vaccines for the African meningitis belt.

Published 6 April 2007 in Clin Vaccine Immunol, 14(4): 451-63.
Full-text of this article is available online (may require subscription).

© 2004-2008 Meningitis Research Today. All Rights Reserved.